Tau-targeting antibodies are also an attractive option in AD treatments, but there is a lack of consensus whether these antibodies are increased in patients with AD, with statistically significant differences in mild cognitive impairment only detected between genders in AD (Krestova et al., 2018). The gene discussed is MAPT; the disease is Alzheimer disease.